Literature DB >> 25578302

[Methotrexate-associated photosensitization].

K Hoffmann1, F Casetti, C Schempp.   

Abstract

BACKGROUND: Methotrexate (MTX), alongside fumaric acid esters, is the most commonly used drug in the systemic therapy of psoriasis in Germany. It is sometimes used in combination with topical therapy and/or phototherapy due to synergistic effects. CASE REPORT: Here we describe a case of phototoxic dermatitis during treatment with MTX. Other cutaneous side effects of MTX include so-called UV recall, radiation recall, and skin tumor formation.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25578302     DOI： 10.1007/s00105-014-3569-6

Source DB:  PubMed          Journal:  Hautarzt        ISSN： 0017-8470            Impact factor:   0.751


  8 in total

1.  Photohydrolysis of methotrexate produces pteridine, which induces poly-G-specific DNA damage through photoinduced electron transfer.

Authors:  Kazutaka Hirakawa; Masahiro Aoshima; Yusuke Hiraku; Shosuke Kawanishi
Journal:  Photochem Photobiol       Date:  2002-11       Impact factor: 3.421

Review 2.  Combination therapy in the treatment of psoriasis.

Authors:  Silja Domm; Ulrich Mrowietz
Journal:  J Dtsch Dermatol Ges       Date:  2010-09-24       Impact factor: 5.584

3.  Solar burn reactivation induced by methotrexate.

Authors:  Kelli J DeVore
Journal:  Pharmacotherapy       Date:  2010-04       Impact factor: 4.705

4.  Ultraviolet recall reaction after total body irradiation, etoposide, and methotrexate therapy.

Authors:  Katherine L Goldfeder; Joshua M Levin; Kenneth A Katz; Loren E Clarke; Alison W Loren; William D James
Journal:  J Am Acad Dermatol       Date:  2006-12-20       Impact factor: 11.527

5.  [S3-guidelines for the treatment of psoriasis vulgaris Update 2011].

Authors:  Alexander Nast; Wolf-Henning Boehncke; Ulrich Mrowietz; Hans-Michael Ockenfels; Sandra Philipp; Kristian Reich; Thomas Rosenbach; Adel Sammain; Martin Schlaeger; Michael Sebastian; Wolfram Sterry; Volker Streit; Matthias Augustin; Ricardo Erdmann; Joachim Klaus; Joachim Koza; Siegrid Müller; Hans-Dieter Orzechowski; Stefanie Rosumeck; Gerhard Schmid-Ott; Tobias Weberschock; Berthold Rzany
Journal:  J Dtsch Dermatol Ges       Date:  2011-06       Impact factor: 5.584

6.  Reactivation of phototoxicity test for psoralens plus ultraviolet A by low-dose methotrexate.

Authors:  H Okamoto; A Fukuda; K Mizuno; N Matsuyoshi; K Fujii; S Imamura
Journal:  Photodermatol Photoimmunol Photomed       Date:  1994-06       Impact factor: 3.135

Review 7.  Drug eruptions: approaching the diagnosis of drug-induced skin diseases.

Authors:  Simon Nigen; Sandra R Knowles; Neil H Shear
Journal:  J Drugs Dermatol       Date:  2003-06       Impact factor: 2.114

8.  European S3-guidelines on the systemic treatment of psoriasis vulgaris.

Authors:  D Pathirana; A D Ormerod; P Saiag; C Smith; P I Spuls; A Nast; J Barker; J D Bos; G-R Burmester; S Chimenti; L Dubertret; B Eberlein; R Erdmann; J Ferguson; G Girolomoni; P Gisondi; A Giunta; C Griffiths; H Hönigsmann; M Hussain; R Jobling; S-L Karvonen; L Kemeny; I Kopp; C Leonardi; M Maccarone; A Menter; U Mrowietz; L Naldi; T Nijsten; J-P Ortonne; H-D Orzechowski; T Rantanen; K Reich; N Reytan; H Richards; H B Thio; P van de Kerkhof; B Rzany
Journal:  J Eur Acad Dermatol Venereol       Date:  2009-10       Impact factor: 6.166
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.